Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.

Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ.

ACS Chem Biol. 2009 Mar 20;4(3):221-31. doi: 10.1021/cb800306y.

PMID:
19206187
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
[PubMed - indexed for MEDLINE]
3.

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Moir DT.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):297-305. Review.

PMID:
16181147
[PubMed - indexed for MEDLINE]
4.

Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).

Lu X, Huang K, You Q.

Expert Opin Ther Pat. 2011 Jul;21(7):1007-22. doi: 10.1517/13543776.2011.581227. Epub 2011 Jun 9. Review.

PMID:
21651455
[PubMed - indexed for MEDLINE]
5.

Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents.

Oliveira JS, Vasconcelos IB, Moreira IS, Santos DS, Basso LA.

Curr Drug Targets. 2007 Mar;8(3):399-411. Review.

PMID:
17348833
[PubMed - indexed for MEDLINE]
6.

The reductase steps of the type II fatty acid synthase as antimicrobial targets.

Zhang YM, Lu YJ, Rock CO.

Lipids. 2004 Nov;39(11):1055-60. Review.

PMID:
15726819
[PubMed - indexed for MEDLINE]
7.

Diversity in enoyl-acyl carrier protein reductases.

Massengo-Tiassé RP, Cronan JE.

Cell Mol Life Sci. 2009 May;66(9):1507-17. doi: 10.1007/s00018-009-8704-7. Review.

PMID:
19151923
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk